Back to News
Market Impact: 0.6
Karyopharm Therapeutics Inc. to be Delisted from Nasdaq Following Chapter 11 Bankruptcy Petitions
Source: Nasdaq
Legal & LitigationCompany FundamentalsCredit & Bond Markets
Karyopharm Therapeutics said it received a written Nasdaq delisting notice on November 4, 2026, following its voluntary Chapter 11 bankruptcy filing. The notice states the company’s securities will be delisted; the provided article text gives no additional financial figures or timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.85
Ticker Sentiment
KPTI-0.95
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook